Need Help?

an integrated molecular study of clear cell renal cell carcinoma (ccRCC) including whole-genome/exome and RNA sequencing as well as array-based gene expression/copy-number/methylation analyses

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000597 Illumina HiSeq 2000 212
EGAD00010000480 Affymetrix_250K(Nsp) - gtype 240
EGAD00010000482 Illumina Infinium HumanMethylation 450K - GenomeStudio 1
EGAD00010000484 Affymetrix_250K(Nsp) - gtype 234
EGAD00010000486 Agilent Human Whole Genome 4x44k v2 - Feature Extraction 101
Publications Citations
ROTS: reproducible RNA-seq biomarker detector-prognostic markers for clear cell renal cell cancer.
Nucleic Acids Res 44: 2016 e1
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Genome Biol 17: 2016 231
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.
Nat Commun 10: 2019 1245
Classification of clear cell renal cell carcinoma based on PKM alternative splicing.
Heliyon 6: 2020 e03440
Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers.
Cancers (Basel) 13: 2021 348
Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning.
iScience 24: 2021 102722
Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Nat Commun 12: 2021 5547
Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma.
Front Oncol 11: 2021 755212
Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome <i>via</i> Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity.
Front Immunol 13: 2022 842069
Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
EBioMedicine 78: 2022 103963